Literature DB >> 35182741

Long-term Follow-up of Hepatitis C Patients Who Achieved Sustained Virologic Response in the Pragmatic PRIORITIZE Study.

Anna S Lok1, Juhi Moon2, Kenneth E Sherman3, Mandana Khalili4, Dawn Fishbein5, K Rajender Reddy6.   

Abstract

Multiple real-world studies have confirmed the safety and efficacy of hepatitis C (HCV) direct-acting antivirals (DAAs); however, few studies have provided data on long-term outcomes of patients without cirrhosis after achieving sustained virologic response (SVR).1-3 The aims of this analysis were to describe, among individuals in the PRIORITIZE Study achieving SVR: (1) the frequency of laboratory testing and imaging during long-term follow-up (LTFU), (2) changes in liver tests, (3) occurrence of hepatic decompensation or hepatocellular carcinoma (HCC) and deaths, and (4) durability of SVR.
Copyright © 2022 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Year:  2022        PMID： 35182741      PMCID： PMC9503088          DOI： 10.1016/j.cgh.2022.01.059

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN： 1542-3565            Impact factor:   13.576


  8 in total

1.  Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy.

Authors:  María Reig; Zoe Mariño; Christie Perelló; Mercedes Iñarrairaegui; Andrea Ribeiro; Sabela Lens; Alba Díaz; Ramón Vilana; Anna Darnell; María Varela; Bruno Sangro; José Luis Calleja; Xavier Forns; Jordi Bruix
Journal:  J Hepatol       Date:  2016-04-13       Impact factor: 25.083

2.  Real-world effectiveness and predictors of sustained virological response with all-oral therapy in 21,242 hepatitis C genotype-1 patients.

Authors:  Lisa I Backus; Pamela S Belperio; Troy A Shahoumian; Timothy P Loomis; Larry A Mole
Journal:  Antivir Ther       Date:  2016-12-09

3.  Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents.

Authors:  Fasiha Kanwal; Jennifer Kramer; Steven M Asch; Maneerat Chayanupatkul; Yumei Cao; Hashem B El-Serag
Journal:  Gastroenterology       Date:  2017-06-19       Impact factor: 22.682

4.  Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals.

Authors:  Fabio Conti; Federica Buonfiglioli; Alessandra Scuteri; Cristina Crespi; Luigi Bolondi; Paolo Caraceni; Francesco Giuseppe Foschi; Marco Lenzi; Giuseppe Mazzella; Gabriella Verucchi; Pietro Andreone; Stefano Brillanti
Journal:  J Hepatol       Date:  2016-06-24       Impact factor: 25.083

5.  Direct-Acting Antiviral Therapy Not Associated With Recurrence of Hepatocellular Carcinoma in a Multicenter North American Cohort Study.

Authors:  Amit G Singal; Nicole E Rich; Neil Mehta; Andrea Branch; Anjana Pillai; Maarouf Hoteit; Michael Volk; Mobolaji Odewole; Steven Scaglione; Jennifer Guy; Adnan Said; Jordan J Feld; Binu V John; Catherine Frenette; Parvez Mantry; Amol S Rangnekar; Omobonike Oloruntoba; Michael Leise; Janice H Jou; Kalyan Ram Bhamidimarri; Laura Kulik; Tram Tran; Hrishikesh Samant; Renumathy Dhanasekaran; Andres Duarte-Rojo; Reena Salgia; Sheila Eswaran; Prasun Jalal; Avegail Flores; Sanjaya K Satapathy; Robert Wong; Annsa Huang; Suresh Misra; Myron Schwartz; Robert Mitrani; Sasank Nakka; Wassim Noureddine; Chanda Ho; Venkata R Konjeti; Alexander Dao; Kevin Nelson; Kelly Delarosa; Usman Rahim; Meher Mavuram; Jesse J Xie; Caitlin C Murphy; Neehar D Parikh
Journal:  Gastroenterology       Date:  2019-01-18       Impact factor: 22.682

6.  Medication Non-adherence in a Prospective, Multi-center Cohort Treated with Hepatitis C Direct-Acting Antivirals.

Authors:  Marina Serper; Donna M Evon; Paul W Stewart; Anna S Lok; Jipcy Amador; Bryce B Reeve; Carol E Golin; Michael W Fried; K Rajender Reddy; Richard K Sterling; Souvik Sarkar; Adrian M Di Bisceglie; Joseph K Lim; David R Nelson; Nancy Reau
Journal:  J Gen Intern Med       Date:  2019-10-28       Impact factor: 5.128

7.  Global real-world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: Analysis of 5552 patients from 12 cohorts.

Authors:  Alessandra Mangia; Scott Milligan; Mandana Khalili; Stefano Fagiuoli; Stephen D Shafran; Fabrice Carrat; Denis Ouzan; George Papatheodoridis; Alnoor Ramji; Sergio M Borgia; Heiner Wedemeyer; Ruggero Losappio; Francisco Pérez-Hernandez; Nicole Wick; Robert S Brown; Pietro Lampertico; Karen Doucette; Ioanna Ntalla; Heribert Ramroth; Michael Mertens; Kim Vanstraelen; Juan Turnes
Journal:  Liver Int       Date:  2020-06-09       Impact factor: 5.828

8.  A Pragmatic, Randomized Controlled Trial of Oral Antivirals for the Treatment of Chronic Hepatitis C: The PRIORITIZE Study.

Authors:  Mark S Sulkowski; Juhi S Moon; Kenneth E Sherman; Giuseppe Morelli; Jama M Darling; Andrew J Muir; Mandana Khalili; Dawn A Fishbein; Federico Hinestrosa; Mitchell L Shiffman; Adrian Di Bisceglie; K Rajender Reddy; Brian Pearlman; Anna S Lok; Michael W Fried; Paul W Stewart; Joy Peter; Summer Wadsworth; Scott Kixmiller; Anquenette Sloan; Monika Vainorius; Patrick M Horne; Larry Michael; Meichen Dong; Donna M Evon; Jodi B Segal; David R Nelson
Journal:  Hepatology       Date:  2021-08-26       Impact factor: 17.425
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.